Eisai (Liaoning) Pharmaceutical Co. Ltd.
https://www.eisai.com.cn/eln/en/index_en.php
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Eisai (Liaoning) Pharmaceutical Co. Ltd.
Leqembi Safety Is Focus Of Three Postmarketing Requirements From US FDA
Required studies will assess the risks of ARIA and intracerebral hemorrhage, as well as safety in ApoE ε4 homozygotes. For the required registry-based study, the FDA suggests use of the ALZ-NET platform with no mention of CMS’ newly established registry, which may lack the level of detailed information needed to satisfy the drug regulator’s request.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Liaoning TianYi Biological Pharmaceutical
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eisai (Liaoning) Pharmaceutical Co. Ltd.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice